Return
Company Page
AptaDir Therapeutics
AptaDir Therapeutics is a Milan-based biopharmaceutical company developing a novel class of RNA inhibitors called DNMTs Interacting RNAs (DiRs) to treat intractable cancers and rare genetic conditions. Its proprietary platform reprograms aberrant DNA methylation at a single-gene level, reactivating previously silenced genes. The company's lead asset, Aptadir Ce-49, targets Myelodysplastic Syndrome (MDS) and is on track to enter clinical trials by end of 2025, with Fragile X Syndrome as a key additional indication.
Company Founded in 2023
Healthtech & Biotech